We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · October 26, 2021

Determinants of Very Severe Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors

European Journal of Cancer


Additional Info

European Journal of Cancer
The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry
Eur. J. Cancer 2021 Oct 06;[EPub Ahead of Print], V Ruste, V Goldschmidt, A Laparra, S Messayke, FX Danlos, P Romano-Martin, S Champiat, AL Voisin, C Baldini, C Massard, S Laghouati, A Marabelle, O Lambotte, JM Michot

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading